Company

GSK Q3 2026 Revenue Rises 5% to GBP 8.9 Billion as Specialty Medicines Surge 15%, Vaccines Stumble on Weak Shingrix China Demand
Finanical ReportsGlaxoSmithKline

GSK Q3 2026 Revenue Rises 5% to GBP 8.9 Billion as Specialty Medicines Surge 15%, Vaccines Stumble on Weak Shingrix China Demand

GlaxoSmithKline Plc (GSK; NYSE: GSK) reported Q3 2026 revenues of GBP 8.89 billion (USD 11.91 billion), up 5% at constant exchange rates (CER), driven by double-digit growth in specialty medicines,…

Hengrui Pharma Q3 2026 Revenue Jumps 20.55% and Non-Recurring Net Profit Nearly Doubles – Innovative Drugs Now Drive 65% of Drug Sales as Generics Shrink

Hengrui Pharma Q3 2026 Revenue Jumps 20.55% and Non-Recurring Net Profit Nearly Doubles – Innovative Drugs Now Drive 65% of Drug Sales as Generics Shrink

Kelun Pharma's Sac-TMT Wins CDE Review Acceptance for Seventh Indication – First-Line Non-Squamous NSCLC Combo with MSD's KEYTRUDA

Kelun Pharma’s Sac-TMT Wins CDE Review Acceptance for Seventh Indication – First-Line Non-Squamous NSCLC Combo with MSD’s KEYTRUDA

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
BioNTech and BMS Reveal Promising Interim Results for Pumitamig in ES‑SCLC
BioNTechBMS

BioNTech and BMS Reveal Promising Interim Results for Pumitamig in ES‑SCLC

Summit Therapeutics Presents 2025 HARMONi Study Results at World Lung Cancer Conference
CancerClinical trial results

Summit Therapeutics Presents 2025 HARMONi Study Results at World Lung Cancer Conference

Guangzhou’s Bio‑Thera Solutions Secures $5.4 Million Milestone from Intas Pharma
Accord BioPharmaBio-Thera Solutions

Guangzhou’s Bio‑Thera Solutions Secures $5.4 Million Milestone from Intas Pharma

FDA Launches Aggressive Campaign to Curb Misleading Drug Advertisements

FDA Launches Aggressive Campaign to Curb Misleading Drug Advertisements

Show More